Cytomegalovirus infection and relative risk of cardiovascular disease (ischemic heart disease, stroke, and cardiovascular death): A meta-analysis of prospective studies up to 2016

Journal of the American Heart Association

Volumn 6, Issue 7, 2017, Pages

  Wang, Haoran ^a   Peng, Geng ^a   Bai, Jing ^a   He, Bing ^a   Huang, Kecheng ^b   Hu, Xinrong ^a   Liu, Dongliang ^a  

^a First Affiliated Hospital of Luohe Medical College   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cardiovascular disease risk factors; Cytomegalovirus; Infectious disease; Meta analysis; Prospective cohort study; Virus

Indexed keywords

ARTICLE; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTERNATIONAL CLASSIFICATION OF DISEASES; INTERRATER RELIABILITY; ISCHEMIC HEART DISEASE; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; VIRUS TITRATION; FEMALE; HEART MUSCLE ISCHEMIA; INCIDENCE; MALE; ODDS RATIO; PROGNOSIS; TIME FACTOR; VIROLOGY;

CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MYOCARDIAL ISCHEMIA; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS;

EID: 85025445118     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.005025     Document Type: Article

References (31)

1. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol. 2008;325:417-470.
2. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43:1143-1151.
3. Xenaki E, Hassoulas J, Apostolakis S, Sourvinos G, Spandidos DA. Detection of cytomegalovirus in atherosclerotic plaques and nonatherosclerotic arteries. Angiology. 2009;60:504-508.
4. Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol. 1994;42:170-174.
5. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet. 1983;2:644-647.
6. Blum A, Giladi M, Weinberg M, Kaplan G, Pasternack H, Laniado S, Miller H. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol. 1998;81:866-868.
7. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
8. Nikitskaya E, Lebedeva A, Ivanova O, Maryukhnich E, Shpektor A, Grivel JC, Margolis L, Vasilieva E. Cytomegalovirus-productive infection is associated with acute coronary syndrome. J Am Heart Assoc. 2016;5:e003759. DOI: 10. 1161/JAHA.116.003759.
9. Liu R, Moroi M, Yamamoto M, Kubota T, Ono T, Funatsu A, Komatsu H, Tsuji T, Hara H, Hara H, Nakamura M, Hirai H, Yamaguchi T. Presence and severity of Chlamydia pneumoniae and cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes. Int Heart J. 2006;47:511-519.
10. Elkind MS, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, Rundek T, Sacco RL, Paik MC. Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol. 2010;67:33-38.
11. Popovic M, Smiljanic K, Dobutovic B, Syrovets T, Simmet T, Isenovic ER. Human cytomegalovirus infection and atherothrombosis. J Thromb Thrombolysis. 2012;33:160-172.
12. Haider AW, Wilson PW, Larson MG, Evans JC, Michelson EL, Wolf PA, O'Donnell CJ, Levy D. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol. 2002;40:1408-1413.
13. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, Dzavik V, McQueen M, Yusuf S; Heart Outcomes Prevention Evaluation Study I. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:251-257.
14. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172:363-371.
15. Savva GM, Pachnio A, Kaul B, Morgan K, Huppert FA, Brayne C, Moss PA; Medical Research Council Cognitive F, Ageing S. Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell. 2013;12:381-387.
16. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke. 1999;30:299-305.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
18. Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-Norfolk cohort. J Infect Dis. 2012;206:1897-1903.
19. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6:e16103.
20. Spyridopoulos I, Martin-Ruiz C, Hilkens C, Yadegarfar ME, Isaacs J, Jagger C, Kirkwood T, von Zglinicki T. CMV seropositivity and T-cell senescence predict increased cardiovascular mortality in octogenarians: results from the Newcastle 85+ study. Aging Cell. 2016;15:389-392.
21. Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G, Novo S. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke. 2006;37:482-486.
22. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48:2787-2792.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
25. Langer G, Meerpohl JJ, Perleth M, Gartlehner G, Kaminski-Hartenthaler A, Schunemann H. [GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables]. Z Evid Fortbild Qual Gesundhwes. 2012;106:357-368.
26. Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer-Norfolk cohort. Clin Infect Dis. 2013;56:1421-1427.
27. Filardo S, Di Pietro M, Farcomeni A, Schiavoni G, Sessa R. Chlamydia pneumoniae-mediated inflammation in atherosclerosis: a meta-analysis. Mediators Inflamm. 2015;2015:378658.
28. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:601-610.
29. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation. 2009;119:3133-3141.
30. Pryzdial EL, Wright JF. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid. Blood. 1994;84:3749-3757.
31. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell. 1990;61:657-662.